Can a Leading Laboratory Unlock the Cause of Gastrointestinal Disease?
Faranak Fattahi’s lab is a national leader in growing stem cells to model peripheral nerves, focusing on gastrointestinal diseases.
University of California San Francisco
Give to UCSFFaranak Fattahi’s lab is a national leader in growing stem cells to model peripheral nerves, focusing on gastrointestinal diseases.
Vissers’ work on RNA tags helped found the field of epitranscriptomics, the study of how chemical marks on RNA, rather than their sequence alone, dictate the function of the molecules.
Balyn Zaro’s lab investigates the cause and consequence of genetic diversity in the immune system, in hopes that her discoveries can lead to better treatments for all patients.
Angela Phillips, PhD, leads research that could help predict future viruses like COVID and the antibodies we might use to treat them.
Emily Goldberg's lab studies what happens during aging to a particular set of immune cells: those embedded in fat tissue. She hypothesizes that changes to these cells during aging could be key to age-related inflammation.
Because proteins can adapt to extremes, Margaux Pinney, PhD, believes they can show how living organisms might adapt to climate change.
Leanne Jones, PhD, is at the forefront of studying how stem cells are influenced by their surrounding environment and directed to differentiate into one type of cell or another – research that’s critical for stem cell therapies to be successful.
Shaeri Mukherjee, PhD, has won the Bowes Biomedical Investigator award, which will provide funding to further her work using bacterial pathogens to identify basic processes inside human cells.
UCSF experts share insights and tips on supporting children with ADHD amidst a shortage of Adderall and other ADHD medications.
UCSF experts discuss the current state of Alzheimer’s treatments and future therapies that may slow progression of the disease.
Researchers have discovered a cellular uptake pathway for larger molecules that delivers cell-permeable drugs efficiently.
Groundbreaking research by UCSF scientists has led to FDA approval of a new therapy that can delay the onset of type 1 diabetes by at least 2 years.